Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lymphoma 43Breast Neoplasms 37Lymphoma, Large B-Cell, Diffuse 29Sarcoma 20Lymphoma, Non-Hodgkin 17Burkitt Lymphoma 16Neuroblastoma 15Leukemia 13HIV Infections 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Hodgkin Disease 11Acquired Immunodeficiency Syndrome 11Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Ovarian Neoplasms 9Multiple Myeloma 9Carcinoma, Hepatocellular 9Lymphoma, Large-Cell, Immunoblastic 8Lymphoma, Follicular 8Liver Neoplasms 8Liposarcoma 7Breast Neoplasms, Male 7Lymphoma, Mantle-Cell 6Lymphoma, Large-Cell, Anaplastic 6Fallopian Tube Neoplasms 6Sarcoma, Kaposi 5Neoplasms, Plasma Cell 5Lymphoma, B-Cell 5Lung Neoplasms 5Histiocytoma, Malignant Fibrous 5Fibrosarcoma 5

Interventions

Specimen Handling 2ribociclib 1exemestane 1durvalumab 1Taxes 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Letrozole 1Immunoglobulin G 1Genetic Testing 1Drug Therapy 1Doxorubicin 1Disulfides 1Cyclophosphamide 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Anatomic Stage II Breast Cancer AJCC v8 × Doxorubicin × Clear all
NCT06058377 2026-06-03

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

National Cancer Institute (NCI)

Phase 3 Recruiting
3,680 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡